Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Ironwood Pharmaceuticals (IRWD) over the last 13 years, with Dec 2024 value amounting to $2.0 million.

  • Ironwood Pharmaceuticals' Current Deferred Revenue was N/A to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 22.44% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $2.0 million for FY2024, which was down 22.44% from $2.6 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Current Deferred Revenue ranged from a high of $2.6 million in FY2023 and a low of $2.0 million during FY2024.
  • In the last 2 years, Ironwood Pharmaceuticals' Current Deferred Revenue had a median value of $2.3 million in 2023 and averaged $2.3 million.
  • Data for Ironwood Pharmaceuticals' Current Deferred Revenue shows a maximum YoY declined of 22.44% (in 2024) over the last 5 years.
  • Ironwood Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $2.6 million in 2023, then fell by 22.44% to $2.0 million in 2024.